STA
JAZZ icon

Summit Trail Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Summit Trail Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.69M Sell
24,830
-985
-4% -$172K 0.07% 180
2025
Q4 		$4.39M Buy
25,815
+3,819
+17% +$585K 0.08% 151
2025
Q3 		$2.9M Buy
21,996
+7,663
+53% +$919K 0.04% 259
2025
Q2 		$1.52M Buy
14,333
+10,973
+327% +$1.19M 0.03% 336
2025
Q1 		$417K Sell
3,360
-1,016
-23% -$133K 0.01% 271
2024
Q4 		$539K Buy
+4,376
New +$516K 0.02% 207
2019
Q1 		– Sell
-15,854
Closed -$1.97M – 115
2018
Q4 		$1.97M Sell
15,854
-118
-0.7% -$17.5K 0.7% 28
2018
Q3 		$2.69M Buy
15,972
+118
+0.7% +$20.3K 0.59% 35
2018
Q2 		$2.73M Buy
+15,854
New +$2.59M 0.96% 16
2018
Q1 		– Sell
-1,175
Closed -$180K – 1070
2017
Q4 		$180K Buy
+1,175
New +$163K 0.02% 455

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Summit Trail Advisors's JAZZ Position: Q1 2026 in Review

Summit Trail Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 3.8% in Q1 2026, selling an estimated $172K and leaving 24,830 shares worth $4.69M. The position accounts for 0.07% of the portfolio, ranked #180.

Summit Trail Advisors first reported a position in JAZZ in Q4 2017 and has held it in 10 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Summit Trail Advisors held 24,830 shares of Jazz Pharmaceuticals worth $4.69M as of Q1 2026.
  • Summit Trail Advisors sold 985 Jazz Pharmaceuticals shares in Q1 2026, an estimated $172K.
  • Jazz Pharmaceuticals made up 0.07% of Summit Trail Advisors's portfolio in Q1 2026, its #180 holding.
  • Summit Trail Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and has held it in 10 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.